Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

NanoViricides inks deal with University of Pittsburgh for ocular resting of drug candidates NanoViricides has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides drug candidates in standard animal models of ocular virus infections.
Contract Research & Services > Contract Services > News
Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News Takeda secures rights to Mersana’s XMT-1522 outside US and Canada Mersana Therapeutics and Takeda Pharmaceutical Company have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the US and Canada.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda
Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News
Takeda secures rights to Mersana’s XMT-1522 outside US and Canada
Mersana Therapeutics and Takeda Pharmaceutical Company have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the US and Canada.
Contract Research & Services > Contract Services > News
Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain
Eisai has entered into a new agreement with Esteve to co-promote Fycompa (perampanel) in Spain from February 2016.
Contract Research & Services > Contract Services > News
Ligand inks OmniAb platform license deal with Tizona Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing next generation therapies for cancer and autoimmune disease.
Contract Research & Services > Contract Services > News
Teva and AbCellera sign deal to discover rare monoclonal antibodies
Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.
Contract Research & Services > Contract Services > News
Eisai acquires license from HUYA to develop HDAC inhibitor HBI-8000
Eisai has entered into an exclusive license agreement with HUYA Bioscience International to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
Contract Research & Services > Contract Services > News
Bristol-Myers Squibb, Pfizer collaborate with Portola to develop andexanet alfa in Japan
Bristol-Myers Squibb and Pfizer have entered into a collaboration agreement with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan.
Contract Research & Services > Contract Services > News
Avera Medical, Epic Sciences partner on cancer precision medicine clinical trials
Epic Sciences and Avera Medical Group have formed a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
Contract Research & Services > Contract Services > News
Radius Health partners with Novartis to evaluate RAD1901 combination regimens in advanced breast cancer
Radius Health has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib), a cyclin-dependent kinase (CDK) 4/6 inhibitor.
Contract Research & Services > Contract Services > News
Myeloma UK partners with SGC to accelerate discovery of myeloma treatment targets
Myeloma UK has entered into a new first-of-its-kind partnership to help bring treatments to myeloma patients faster.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests